Literature DB >> 26841787

Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs.

Carlo Patrono1.   

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) include aspirin, other traditional NSAIDs, and coxibs. Evidence obtained during the past 10 years has focused attention on the cardiovascular hazard associated with coxibs and some traditional NSAIDs. The large randomized trials of prolonged coxib treatment added importantly to information provided by epidemiological studies that had previously associated regular use of NSAIDs with increased blood pressure and enhanced risk of congestive heart failure, and identified an increased risk of myocardial infarction as a class effect of cyclooxygenase-2 inhibitors. The aim of this article is to review the cardiovascular effects of aspirin, other traditional NSAIDs, and coxibs, to discuss the mechanisms underlying these effects, and to provide a clinical perspective on the cardiovascular hazard associated with their use.

Entities:  

Keywords:  Aspirin; Atherothrombosis; Coxib; Cyclooxygenase inhibitors; Diclofenac; Heart failure; Ibuprofen; Naproxen

Mesh：

Substances：

Year:  2016        PMID： 26841787     DOI： 10.1007/s11886-016-0702-4

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  38 in total

1.  Improvement of renal function with selective thromboxane antagonism in lupus nephritis.

Authors:  A Pierucci; B M Simonetti; G Pecci; G Mavrikakis; S Feriozzi; G A Cinotti; P Patrignani; G Ciabattoni; C Patrono
Journal:  N Engl J Med       Date:  1989-02-16       Impact factor: 91.245

2.  Parecoxib, valdecoxib, and cardiovascular risk.

Authors:  Curt D Furberg; Bruce M Psaty; Garret A FitzGerald
Journal:  Circulation       Date:  2005-01-17       Impact factor: 29.690

3.  Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

Authors:  Nancy A Nussmeier; Andrew A Whelton; Mark T Brown; Richard M Langford; Andreas Hoeft; Joel L Parlow; Steven W Boyce; Kenneth M Verburg
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

4.  Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Carlo Patrono; Colin Baigent; Jack Hirsh; Gerald Roth
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

Review 5.  The role of aspirin in cancer prevention.

Authors:  Michael J Thun; Eric J Jacobs; Carlo Patrono
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

Review 6.  Aspirin as an antiplatelet drug.

Authors:  C Patrono
Journal:  N Engl J Med       Date:  1994-05-05       Impact factor: 91.245

7.  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.

Authors:  P Patrignani; P Filabozzi; C Patrono
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

8.  Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

Authors:  B F McAdam; F Catella-Lawson; I A Mardini; S Kapoor; J A Lawson; G A FitzGerald
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

9.  Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man.

Authors:  G A FitzGerald; J A Oates; J Hawiger; R L Maas; L J Roberts; J A Lawson; A R Brash
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

10.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321
View more
  7 in total

Review 1.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

Review 2.  Analgesia for Sheep in Commercial Production: Where to Next?

Authors:  Alison Small; Andrew David Fisher; Caroline Lee; Ian Colditz
Journal:  Animals (Basel)       Date:  2021-04-14       Impact factor: 2.752

3.  Rational design of biodegradable sulphonamide candidates treating septicaemia by synergistic dual inhibition of COX-2/PGE2 axis and DHPS enzyme.

Authors:  Nada H El-Dershaby; Soad A El-Hawash; Shaymaa E Kassab; Hoda G Dabees; Ahmed E Abdel Moneim; Ibrahim A Abdel Wahab; Mohammad M Abd-Alhaseeb; Mostafa M M El-Miligy
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

4.  Ibuprofen arginate retains eNOS substrate activity and reverses endothelial dysfunction: implications for the COX-2/ADMA axis.

Authors:  Nicholas S Kirkby; Abel Tesfai; Blerina Ahmetaj-Shala; Hime H Gashaw; Walkyria Sampaio; Gisele Etelvino; Nádia Miricéia Leão; Robson A Santos; Jane A Mitchell
Journal:  FASEB J       Date:  2016-09-06       Impact factor: 5.191

5.  Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival.

Authors:  Elisabetta Panza; Paola De Cicco; Giuseppe Ercolano; Chiara Armogida; Giosuè Scognamiglio; Anna Maria Anniciello; Gerardo Botti; Giuseppe Cirino; Angela Ianaro
Journal:  Oncotarget       Date:  2016-08-30

Review 6.  Effects of Aspirin on Endothelial Function and Hypertension.

Authors:  Mikhail S Dzeshka; Alena Shantsila; Gregory Y H Lip
Journal:  Curr Hypertens Rep       Date:  2016-11       Impact factor: 5.369

7.  Salidroside suppresses solar ultraviolet-induced skin inflammation by targeting cyclooxygenase-2.

Authors:  Dan Wu; Ping Yuan; Changshu Ke; Hua Xiong; Jingwen Chen; Jinguang Guo; Mingmin Lu; Yanyan Ding; Xiaoming Fan; Qiuhong Duan; Fei Shi; Feng Zhu
Journal:  Oncotarget       Date:  2016-05-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.